Tremelimumab + Durvalumab Chemotherapy Naive CRPC

• Status: Recruiting
• Trial end date: 0000-00-00

Summary

The goal of this clinical research study is to study the safety and tolerability of durvalumab and tremelimumab when given to participants with metastatic (has spread) castration-resistant prostate cancer.

• Phase: Phase 2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: MedImmune LLC
• Treatments: Antibodies, Monoclonal; Tremelimumab